After topping out at about 3.5%, the Stock Challenge Index has headed south, barely hanging onto positive gains as investors bail on speculative bets. But, one Stock Challenger saw a move coming and is well ahead!
Longtime member ‘Lubie1953‘ is known for huge performances in our monthly Stock Challenge. So, it comes as little surprise that they are far and away our leader at the halfway point. Lubie’s selection of ImmunoGen was timed to perfection. On May 3rd, the company announced that its,
“…lead drug Elahere (mirvetuximab soravtansine) received an accelerated FDA approval in November 2022 to treat adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.”
Click here to read the entire press release.
Lubie1953 is up a whopping 69.60% thus far in May!
ImmunoGen – 3-Month Chart
Lubie1953 came close to glory in December of 2022 when their selection of Ra Medical Systems almost delivered the crown. Ra Medical jammed 140% that month, but Lubie’s other selection wasn’t enough to take top spot…
But, Lubie is no stranger to victory, especially when gold bullion is on the line. In December of 2021, Lubie1953 selected Engage Mobility, a stock that turned out to be a triple-digit gainer with an approximate 240% return on the month.
While Lubie’s other selection that month tanked, it didn’t matter. Their combined average return of nearly 100% landed Lubie a 1-ounce gold maple leaf coin and the status of Champion in December of 2021.
Can Lubie do it again? Members ‘larry norgren‘ and ‘PAULETTO‘ may have something to say about it. While in 2nd and 3rd, respectively, the second half of May’s Stock Challenge awaits! And let us not forget that PAULETTO won April’s Stock Challenge and clearly has momentum!
There are only a few days left to make a SWAP! Take advantage of this tool to lock in gains, or… stop the bleeding and dump your loser(s).
Click here to learn more about swapping if you haven’t tried it out already.
Good luck, and stay tuned in!